Cholesterol is known to slow the activity of tuberculosis, and the new research suggests a modified version of the compound could stop the bacteria responsible for the deadly infections from growing altogether.
“The results presented here thus implicate a distinct and more robust mechanism of growth inhibition,” study authors concluded. “They define a new paradigm for the development of agents that can, at least in culture, block the growth of Mycobacterium tuberculosis. Further exploration of this paradigm is a promising route for the development of therapeutically useful inhibitors.”
The findings are published in the Journal of Biological Chemistry.
More articles on infection control:
CDC worker possibly infected with laboratory-acquired Salmonella
5 things to know about Zika misperceptions in the US
Lab-confirmed flu cases begin to fall, but overall rates remain elevated
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
